Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion

30 May 2015

Abstract excerpt

// Huabo Wang 1 , Lokendra Sharma 1 , Jie Lu 1 , Paul Finch 1 , Steven Fletcher 2,3 and Edward V. Prochownik 1,4,5 1 Division of Hematology/Oncology, Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh PA, USA 2 Department of Pharmaceutical Sciences, The University of Maryland School of Pharmacy, Baltimore, MD, USA 3 The Greenebaum Cancer Center, Baltimore MD, USA 4...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26036281
DOI: 10.18632/oncotarget.4327

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletionPMID 26036281Read ↗

Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoidsSemantic proximity Read ↗

Mitotic Poisons In Cancer PharmacotherapySemantic proximity Read ↗

Isoquinolines alkaloids and cancer metabolism: Pathways and targets to novel chemotherapySemantic proximity Read ↗

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsSemantic proximity Read ↗

MYC: there is more to it than cancerSemantic proximity Read ↗

The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagySemantic proximity Read ↗

Strategies to target the cancer driver MYC in tumor cellsSemantic proximity Read ↗

BCOR Mutations Define a Therapeutic Vulnerability to DHODH Inhibition in Acute Myeloid LeukemiaSemantic proximity Read ↗

MYC modulators in cancer: a patent reviewSemantic proximity Read ↗

The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagySemantic proximity Read ↗

Fighting Tumor Cell Survival: Advances in the Design and Evaluation of Pim InhibitorsSemantic proximity Read ↗

Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.